NasdaqGS - Delayed Quote USD

Zynex, Inc. (ZYXI)

2.1700
+0.0200
+(0.93%)
At close: 4:00:01 PM EDT
2.1700
0.00
(0.00%)
After hours: 4:05:09 PM EDT
Loading Chart for ZYXI
  • Previous Close 2.1500
  • Open 2.1700
  • Bid 1.5900 x 200
  • Ask 2.7500 x 200
  • Day's Range 2.1100 - 2.2480
  • 52 Week Range 1.6600 - 11.0800
  • Volume 102,846
  • Avg. Volume 306,665
  • Market Cap (intraday) 65.618M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2400
  • Earnings Date Jul 23, 2025 - Jul 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jan 5, 2022
  • 1y Target Est 6.00

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

www.zynex.com

1,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZYXI

View More

Performance Overview: ZYXI

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZYXI
72.91%
S&P 500 (^GSPC)
0.08%

1-Year Return

ZYXI
79.68%
S&P 500 (^GSPC)
12.74%

3-Year Return

ZYXI
69.82%
S&P 500 (^GSPC)
46.29%

5-Year Return

ZYXI
86.90%
S&P 500 (^GSPC)
108.74%

Compare To: ZYXI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZYXI

View More

Valuation Measures

Annual
As of 5/12/2025
  • Market Cap

    65.01M

  • Enterprise Value

    114.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.40

  • Price/Book (mrq)

    3.13

  • Enterprise Value/Revenue

    0.66

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.30%

  • Return on Assets (ttm)

    -4.11%

  • Return on Equity (ttm)

    -27.52%

  • Revenue (ttm)

    172.4M

  • Net Income Avi to Common (ttm)

    -7.41M

  • Diluted EPS (ttm)

    -0.2400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    23.85M

  • Total Debt/Equity (mrq)

    351.59%

  • Levered Free Cash Flow (ttm)

    7.68M

Research Analysis: ZYXI

View More

Company Insights: ZYXI

Research Reports: ZYXI

View More

People Also Watch